Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico  by Schmulson, M. et al.
RS
C
a
i
M
a
U
b
c
R
A
a
t
M
2
tevista de Gastroenterología de México. 2016;81(4):236--239
www.elsevier.es/rgmx
REVISTA  DE
DE MEXICO
GASTROENTEROLOGIA´
´
HORT COMMUNICATION
linical  experience  with  the use of  anti-CdtB
nd anti-vinculin  antibodies  in patients  with  diarrhea
n Mexico
. Schmulsona,b,∗, R. Balbuenac, C. Corona de Lawc
Laboratorio  de  Hígado,  Páncreas  y  Motilidad  (HIPAM),  Unidad  de  Investigación  en  Medicina  Experimental,  Facultad  de  Medicina,
niversidad Nacional  Autónoma  de  México  (UNAM),  Mexico  City,  Mexico
Clínica  Lomas  Altas,  SC,  Mexico  City,  Mexico
Laboratorio  Biomédica  de  Referencia,  Mexico  City,  Mexico
eceived  14  April  2016;  accepted  6  July  2016
vailable  online  25  October  2016
KEYWORDS
Biomarkers;
Anti-CdtB/anti-
vinculin;
Diagnosis;
Irritable  bowel
syndrome
with  diarrhea;
Chronic  diarrhea
Abstract
Introduction:  Circulating  anti-CdtB/anti-vinculin  antibodies  have  been  validated  as  biomarkers
to distinguish  IBS-D  from  IBD,  but  there  is  no  experience  with  them  in  Latin  America.
Materials and  methods:  The  analysis  was  carried  out  on  patients  seen  at  a  FGIDs/motility  clinic
over the  last  7  months  for  diarrhea  with  abdominal  pain  and/or  bloating  who  were  tested  for
these antibodies.  The  patients  were  diagnosed  according  to  the  Rome  III  criteria  or  with  organic
disorders, and  those  presenting  with  IBS  were  further  classiﬁed  as  post-infectious  (PI)  or  non-PI
IBS.
Results: Thirty  patients  were  studied.  Positive  biomarkers  were  found  in  IBS-D  y  IBS-D  Overlap
(58.8%) and  IBS-M  (33.3%),  with  no  differences  between  PI-IBS  (71.4%)  vs.  non  PI-IBS  (41.7%)
subjects  (P=.21).  There  was  no  positivity  in  patients  with  other  FGIDs  or  organic  diarrhea,  except
for one  with  small  intestinal  bacterial  overgrowth  (SIBO).
Conclusions:  Our  ﬁndings  support  the  use  of  this  test  as  a  ﬁrst-line  diagnostic  tool  to  conﬁrm
the presence  of  IBS-D/IBS-M  according  to  the  Rome  III  criteria.
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Experiencia  clínica  con  el  uso  de  los  anticuerpos  anti-CdtB  y  anti-vinculina
en  pacientes  con  diarrea  en  México
Resumen
Introducción:  Se  ha  validado  el  uso  de  los  anticuerpos  anti-CdtB/anti-vinculina  como  biomar-
cadores para  discriminar  el  SII-D  de  la  EII,  más  no  hay  experiencia  con  ellos  en  Latinoamérica.
Materiales  y  métodos:  Se  analizaron  pacientes  que  consultaron  a  una  clínica  de  TGIF/motilidad
en los  últimos  7  meses  por  diarrea  con  dolor/distensión  abdominal,  y  a  quienes  se  les  solicitó
estos anticuerpos.  Los  pacientes  fueron  diagnosticados  mediante  los  criterios  de  Roma  III  o  con
trastornos  orgánicos.  Se  clasiﬁcaron  a  los  pacientes  con  SII  en  SII-post  infeccioso  (PI)  o  SII-no
PI.
Resultados:  Treinta  pacientes  fueron  estudiados.  Se  encontraron  biomarcadores  positivos  en
sujetos con  SII-D  y  SII-D  con  sobreposición  (58.8%)  y  SII-M  (33.3%),  sin  diferencias  entre  aquellos
con SII-PI  (71.4%)  vs.  SII-no  PI  (41.7%)  (p  =  0.21).  No  hubo  positividad  en  pacientes  con  otros  TGIF
o diarrea  orgánica,  excepto  en  uno  con  sobrecrecimiento  bacteriano  en  el  intestino  delgado
(SBID).
Conclusión:  Nuestros  datos  apoyan  el  uso  de  esta  prueba  como  una  herramienta  de  diagnóstico
de primera  línea  para  conﬁrmar  la  presencia  de  SII-D/SII-M  según  los  criterios  de  Roma  III.
© 2016  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Publicado  por  Masson  Doyma  Me´xico  S.A.
Este es  un  art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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iIntroduction
The  multidimensional  clinical  proﬁle  (MDCP)  has  recently
been  published  by  The  Rome  Foundation  to  capture  the
full  dimensionality  of  patients  with  functional  gastrointesti-
nal  disorders  (FGIDs)  and  plan  an  individualized  treatment.1
The  MDCP  comprises  ﬁve  categories:  1.  Categorical  diagno-
sis  (Rome  III  criteria);  2.  Clinical  modiﬁers  (e.g.  bowel  habit
subtype:  irritable  bowel  syndrome  with  diarrhea  [IBS-D],
with  constipation  [IBS-C],  mixed-IBS  [IBS-M],  post-infectious
[PI-IBS],  gluten  sensitivity);  3.  Self-perceived  impact  (i.e.
mild,  moderate,  and  severe);  4.  Psychosocial  inﬂuences
(e.g.  DSM-5  categories,  history  of  abuse);  and  5.  Physiologic
modiﬁers  and  biomarkers  (which  may  enhance  the  under-
standing  of  the  diagnosis  or  have  treatment  implications).1
Circulating  antibodies  to  cytolethal  distending  toxin  B
(CdtB)  and  vinculin  have  been  validated  in  the  United  States
as  biomarkers  to  distinguish  IBS-D  from  inﬂammatory  bowel
disease  (IBD).2 CdtB  is  produced  by  bacteria  that  cause
acute  gastroenteritis  including  Campylobacter,  Salmonella
typhi,  Escherichia  coli, and  Shigella  dysenteriae  species
species.3 A  post-C. jejuni  animal  model  demonstrated  that
host  antibodies  to  CdtB  cross-react  with  vinculin  in  the
gut,  producing  a  PI-IBS-like  phenotype.4,5 Therefore,  anti-
CdtB/anti-vinculin  antibodies  were  investigated  in  Rome  III
IBS-D  patients  and  compared  with  patients  with  IBD,  celiac
disease  (CD),  and  healthy  controls.  An  optical  density  (OD)
≥  2.80  for  the  anti-CdtB  antibody  and  ≥  1.68  for  the  anti-
vinculin  antibody  provided  a  speciﬁcity  of  91.6%  and  83.8%,
respectively,  for  discriminating  IBS-D.2 If  either  one  were
present,  the  test  was  considered  positive.There  is  no  clinical  experience  with  these  biomark-
ers  in  Latin  America.  However,  a  cost-minimization  model
showed  that  using  them  as  ﬁrst-line  diagnostic  investiga-
tion  in  patients  suspected  of  having  IBS-D  in  Mexico  lowered
u
m
w
che  costs  by  16.3%,  with  the  possibility  of  reaching  a
5%  savings.6 Furthermore,  the  recently  published  Mexican
onsensus  on  IBS  acknowledged  that  the  anti-CdtB/anti-
inculin  antibodies  were  well  studied  and  validated,
lthough  no  recommendations  were  provided  regarding  their
se  as  diagnostic  tools.7 Therefore,  we  sought  to  describe
erein  the  clinical  experience  in  the  use  of  these  biomarkers
n  patients  seen  at  a  private  FGIDs/Motility  Clinic  in  Mexico
ity.
aterials and methods
e  retrospectively  reviewed  the  clinical  charts  of  patients
ith  chronic  diarrhea  tested  for  the  anti-CdtB/anti-vinculin
ntibodies  as  part  of  their  diagnostic  work-up  between
/09/2015  (when  the  biomarkers  became  available)  and
1/03/2016.  Patients  were  seen  by  one  gastroenterologist
MS)  and  were  diagnosed  with  IBS-D,  IBS-M,  functional  diar-
hea,  or  unspeciﬁed  functional  bowel  disorder  (UFBD)  if
hey  met  the  respective  Rome  III  criteria,  and  were  fur-
her  classiﬁed  as  PI-IBS  if  they  had  a  previous  history  of
nfectious  gastroenteritis  as  a  triggering  factor.  Patients  that
id  not  have  any  of  the  above  disorders  received  organic
iagnoses  according  to  their  clinical  presentation  and  other
ests  (e.g.  CD  serology,  upper  endoscopy,  colonoscopy,  duo-
enal  and/or  colonic  biopsies,  small  bowel  transit,  etc).  We
escribed  the  prevalence  of  positive  anti-CdtB/anti-vinculin
ntibodies  and  OD  values  according  to  diagnoses,  especially
n  IBS,  and  between  PI-IBS  and  non-PI-IBS  subjects.  Categor-
cal  variables  were  reported  in  percentages  and  compared
sing  the  X2 test.  Continuous  variables  were  expressed  in
edian  and  range  and  mean  ±  SD  when  appropriate,  and
ere  compared  using  the  Student’s  t  test.  A  p <  0.05  was
onsidered  statistically  signiﬁcant.
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Table  1  Positive  anti-CdtB  and/or  anti-vinculin  antibodies  in  patients  with  diarrhea-related  IBS  and  others.
Diagnosis  No.  Median  age
(range)
Sex
W/M
(No.)
PI
(No.)
Anti-CdtB
and/or
Anti-Vinculin
antibodies
(positive:  No.)
Anti-CdtB
antibody
only
(positive:  No.)
Anti-Vinculin
antibody  only
(positive:  No.)
Both
antibodies
(positive:  No.)
IBS-D  14  34  (16-65)  9/5  4  7  3  4  –
IBS-D Overlapa 3  43  (26-56)  2/1  1  3  1  1  1
IBS-M 3  45  (27-75)  2/1  2  1  –  1  –
Functional  Diarrhea  5  66  (44-81)  3/2  1  –  –  –  –
UFBD 2  54  (51-57) 1/1  –  –  –  –  –
Microscopic  Colitis 1  26  1/–  –  –  –  –  –
Prokinetic  Agent 1  54  1/–  –  –  –  –  –
SIBO-Duodenal
Diverticula
1 82  1/–  –  1  –  –  –
Total 30  44.5  (16-82)  20/10  8  12  4  6  1
IBS: irritable bowel syndrome; IBS-D: irritable bowel syndrome with diarrhea; IBS-M: mixed irritable bowel syndrome; M: men; PI:
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mpost-infectious; SIBO: small intestinal bacterial overgrowth; UFBD
a CD: 1, TS: 1, MC: 1. The IBS-D Overlap with MC patient was po
esults
 total  of  30  patients  were  studied.  Their  mean  age  was  49.1
 17.5  years  and  63.3%  were  women.  The  majority  of  the
nitial  diagnoses  were  IBS-D  (N):  14;  functional  diarrhea:  5;
BS-M:  3;  UFBD:  2;  non-functional  chronic  diarrhea:  2;  micro-
copic  colitis  (MC):  2;  tropical  sprue  (TS):  1;  and  CD:  1.  Those
atients  with  TS,  CD,  and  one  with  MC,  previously  responded
o  the  speciﬁc  treatments  for  those  conditions  and  then
eveloped  relapsing  diarrhea  with  abdominal  pain/bloating
onsistent  with  IBS-D  (herein  labeled  as  IBS-D  Overlap).
verall,  20  patients  were  diagnosed  with  IBS  (Table  1).
A  positive  biomarker  was  present  in  47.1%  of  the  IBS-
 patients,  in  all  of  the  patients  with  IBS-D  Overlap,  and
n  33.3%  of  those  presenting  with  IBS-M  (Table  1).  There
ere  no  positive  results  in  patients  with  functional  diar-
hea,  UFBD,  MC,  or  in  a  patient  with  diarrhea  that  was  later
ound  to  be  a  side  effect  of  prucalopride.  One  exception  was
n  82-year-old  woman  with  diverticula  in  the  second  and
hird  segments  of  the  duodenum,  who  tested  positive  for
he  anti-CdtB  antibody.  She  was  diagnosed  with  secondary
mall  intestinal  bacterial  overgrowth  (SIBO).
Thirty-ﬁve  percent  of  the  IBS  patients  had  PI-IBS.
owever,  positive  biomarkers  were  present  in  the  PI-IBS  sub-
ects:  5/7  (71.4%),  as  well  as  in  the  non-PI-IBS  ones:  5/12
41.7%),  p  =  0.21.  In  addition,  there  were  no  differences  in
he  OD  values  between  the  PI-IBS  patients  vs.  the  non-PI-IBS
atients  for  the  anti-CdtB  (3.019  ±  0.189  vs.  2.98.6  ±  0.232,
 = 0.69)  and  the  anti-vinculin  (2.224  ±  0.616  vs.  2.151  ±
.503,  p  =  0.14)  antibodies.
onclusions
n  this  clinical  experience  in  Mexico  with  anti-CdtB/anti-
inculin  antibody  testing  on  a  small  number  of  patients,  only
hose  subjects  with  a  diarrhea-related  IBS  diagnosis  accord-
ng  to  Rome  III  had  a  positive  result.  In  contrast,  no  patients
ith  other  diarrhea-related  FGIDs  or  organic  diarrhea
a
n
i
epeciﬁed functional bowel disorder; W: women.
 for both the anti-CdtB antibody and the anti-vinculin antibody.
ithout  IBS-D  Overlap  were  positive.  Anti-CdtB/anti-
inculin  antibodies  were  present  in  8  patients  (47.1%)  with
‘pure’’  IBS.  However,  if  we  add  the  positivity  among  those
ith  IBS-D  Overlap,  55%  of  all  patients  with  a  diarrhea-
elated  IBS  diagnosis  were  positive.  These  results  are  similar
o  the  58.6%  found  by  Pimentel  et  al.  in  their  validation
tudy.2
There  was  only  one  patient  with  organic  diarrhea,  pre-
umably  having  SIBO  secondary  to  duodenal  diverticula,
hat  tested  positive  for  the  anti-CdtB  antibody.  This  can
e  explained  by  the  hypothetical  pathophysiologic  mech-
nism  underlying  the  presence  of  these  antibodies.  In  a
I-IBS  rat  model,4 a  signiﬁcant  reduction  of  interstitial  cells
f  Cajal  (ICCs)  was  observed  and  SIBO  was  developed.8
here  was  also  a  cross-reaction  of  anti-CdtB  antibodies
ith  vinculin,5 a  cytosolic  protein  present  in  ICCs  and
yenteric  ganglia.9 Vinculin  is  also  related  to  actin  that
inds  to  cadherins,  which  are  necessary  for  intestinal
mooth  muscle  contraction.9 The  loss  of  vinculin,  ICCs,  and
yenteric  ganglia  probably  decreased  small  bowel  motil-
ty,  leading  to  the  development  of  bacterial  overgrowth.5,8
his  may  explain  the  positive  anti-CdtB  antibody  in  our
atient.
Not  only  did  we  ﬁnd  positive  anti-CdtB  or  anti-vinculin
ntibodies  in  the  PI-IBS  subgroup,  but  also  in  the  non-PI-
BS  patients.  This  suggests  the  possible  relation  of  other
echanisms  not  associated  with  a  previous  enteric  infec-
ion.  If  anti-CdtB  antibodies  cross-react  with  vinculin,  the
resence  of  anti-vinculin  antibodies  needs  to  be  explained.
ne  may  speculate  that  the  anti-CdtB  antibody  alters  the
roperties  of  vinculin  and  therefore  anti-vinculin  antibodies
re  produced.  If  that  is  the  scenario,  both  antibodies  should
e  present  in  every  patient,  which  was  not  the  case  in  the
alidation  study  or  in  our  case  series.  Thus,  an  autoimmune
echanism  could  explain  the  generation  of  anti-vinculin
ntibodies.  In  fact,  a  previous  study  found  that  anti-enteric
euronal  antibodies  were  more  frequent  in  IBS  patients  than
n  controls,  resulting  in  the  proposal  of  autoimmune  degen-
rative  neuropathy.10
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10. Wood JD, Liu S, Drossman DA, et al. Anti-enteric neuronal anti-Clinical  experience  with  the  use  of  anti-CdtB  and  anti-vincu
The  present  results  have  implications  in  clinical  practice.
The  inclusion  of  this  blood  panel  in  the  diagnostic  process  of
patients  with  IBS  according  to  Rome  III  has  the  potential  for
signiﬁcant  cost  savings,  because  unnecessary  testing  to  rule
out  organic  causes  of  chronic  diarrhea  would  be  avoided.6
Moreover,  an  objective  result  would  most  likely  be  reassuring
to  patients.  Nevertheless,  our  study  has  some  limitations.
First,  it  is  a  small  retrospective  series  and  not  all  of  the
patients  had  the  same  diagnostic  tests  and  procedures  to
rule  out  other  possible  comorbidities.  Second,  we  only  had
two  cases  of  MC,  and  the  behavior  of  the  anti-CdtB/anti-
vinculin  antibody  in  a  disease  characterized  by  low-grade
inﬂammation  that  could  trigger  autoimmunity  is  unknown.
However,  our  patient  with  IBS-D  that  overlapped  with  MC  was
positive  for  both  antibodies,  whereas  the  patient  with  MC,
alone,  was  not.  Third,  no  patient  with  IBD  was  studied,  given
that  it  is  unethical  to  perform  this  test  in  patients  previously
diagnosed  through  the  use  of  other  validated  biomarkers,  as
was  the  case  with  our  IBD  patients.
In  conclusion,  more  than  half  of  this  small  group  of
patients  with  diarrhea-related  IBS  according  to  the  Rome  III
criteria  was  positive  for  the  anti-CdtB  and/or  anti-vinculin
antibody,  regardless  of  PI-IBS.  These  ﬁndings  support  the
use  of  this  test  as  a  ﬁrst-line  diagnostic  tool  to  conﬁrm
the  IBS-D/IBS-M  Rome  III  diagnosis  in  the  patients  that  test
positive.  Future  studies  are  warranted  to  determine  if  the
antibody  levels  can  be  used  to  monitor  and  predict  treat-
ment  response  and/or  IBS  recurrence.
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